Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-Year results from GAIT

Annals of the Rheumatic Diseases

Volumn 69, Issue 8, 2010, Pages 1459-1464

  Sawitzke, Allen D ^a   Shi, Helen ^b   Finco, Martha F ^a   Dunlop, Dorothy D ^c   Harris, Crystal L ^d   Singer, Nora G ^e   Bradley, John D ^f   Silver, David ^g   Jackson, Christopher G ^a   Lane, Nancy E ^h   Oddis, Chester V ⁱ   Wolfe, Fred ^j   Lisse, Jeffrey ^k   Furst, Daniel E ^l   Bingham, Clifton O ^m   Reda, Domenic J ^b   Moskowitz, Roland W ^e   Williams, H James ^a   Clegg, Daniel O ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Hines VA Cooperative Studies Program Coordinating Center   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d University of New Mexico   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f INDIANA UNIVERSITY   (United States)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF PITTSBURGH   (United States)

^j ARTHRITIS RESEARCH CENTER FOUNDATION   (United States)

^k UNIVERSITY OF ARIZONA   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CHONDROITIN SULFATE; GLUCOSAMINE; PLACEBO;

ABDOMINAL ABSCESS; ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART PALPITATION; HIP ARTHROPLASTY; HUMAN; HYPERTENSION; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRANSIENT ISCHEMIC ATTACK; UNITED STATES;

AGED; CHONDROITIN SULFATES; CYCLOOXYGENASE 2 INHIBITORS; DIETARY SUPPLEMENTS; DRUG COMBINATIONS; FEMALE; GLUCOSAMINE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 77955444703     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.120469     Document Type: Article

References (33)

1. Simon LS. Osteoarthritis: a review. Clin Cornerstone 1999;2:26-37.
2. Gregory PJ, Sperry M, Wilson AF. Dietary supplements for osteoarthritis. Am Fam Physician 2008;77:177-84.
3. Kamath CC, Kremers HM, Vanness DJ, et al. The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value Health 2003;6:144-57.
4. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil 2008;16:137-62.
5. Rostom A, Muir K, Dubé C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007;5:818-28, 828.e1-5; quiz 768.
6. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795-808.
7. Sawitzke AD, Shi H, Finco MF, et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum 2008;58:3183-91.
8. Bellamy N. Pain assessment in osteoarthritis: experience with the WOMAC osteoarthritis index. Semin Arthritis Rheum 1989;18(Suppl 2):14-17.
9. Pham T, van der Heijde D, Altman RD, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthr Cartil 2004;12:389-99.
10. Expert Working Group (Efficacy) of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. FDA Center for Drug Evaluation and Research, 2007.
11. Hochberg Y, Tamhane AC. Multiple comparison procedures. New York, USA: John Wiley & Sons, 1987.
12. Hogan JW, Roy J, Korkontzelou C. Handling drop-out in longitudinal studies. Stat Med 2004;23:1455-97.
13. Bruyere O, Reginster JY. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging 2007;24:573-80.
14. Bennett AN, Crossley KM, Brukner PD, et al. Predictors of symptomatic response to glucosamine in knee osteoarthritis: an exploratory study. Br J Sports Med 2007;41:415-19.
15. Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005;2:CD002946.
16. Poolsup N, Suthisisang C, Channark P, et al. Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials. Ann Pharmacother 2005;39:1080-7.
17. Reginster JY, Bruyere O, Henrotin Y. New perspectives in the management of osteoarthritis. structure modification: facts or fantasy? J Rheumatol Suppl 2003;67:14-20.
18. Houpt JB, McMillan R, Wein C, et al. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999;26:2423-30.
19. Leeb BF, Schweitzer H, Montag K, et al. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000;27:205-11.
20. Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003;163:1514-22.
21. Scharf Y, Nahir M, Schapira D, et al. A comparative study of naproxen with diclofenac sodium in osteoarthrosis of the knees. Rheumatol Rehabil 1982;21:167-70.
22. Williams HJ, Ward JR, Egger MJ, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum 1993;36:1196-206.
23. Dieppe P, Cushnaghan J, Jasani MK, et al. A two-year, placebo-controlled trail of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee joint. Br J Rheumatol 1993;32:595-600.
24. Fleischmann R, Tannenbaum H, Patel NP, et al. Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis. BMC Musculoskelet Disord 2008;9:32.
25. Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095-105.
26. Pavelká K, Gatterová J, Olejarová M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002;162:2113-23.
27. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-6.
28. Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006;114:1028-35.
29. Poddubnyy DA, Song IH, Sieper J. The safety of celecoxib in ankylosing spondylitis treatment. Expert Opin Drug Saf 2008;7:401-9.
30. Zhang W, Robertson J, Jones AC, et al. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 2008;67:1716-23.
31. Buckland-Wright JC, Messent EA, Bingham CO 3rd, et al. A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford) 2007;46:257-64.
32. Bingham CO 3rd, Buckland-Wright JC, Garnero P, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006;54:3494-507.
33. Bingham CO 3rd, Sebba AI, Rubin BR, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 2007;46:496-507.